PT3060252T - Utilização de moléculas de ligação de semaforina-4d para tratar distúrbios neurodegenerativos - Google Patents

Utilização de moléculas de ligação de semaforina-4d para tratar distúrbios neurodegenerativos

Info

Publication number
PT3060252T
PT3060252T PT148550742T PT14855074T PT3060252T PT 3060252 T PT3060252 T PT 3060252T PT 148550742 T PT148550742 T PT 148550742T PT 14855074 T PT14855074 T PT 14855074T PT 3060252 T PT3060252 T PT 3060252T
Authority
PT
Portugal
Prior art keywords
semaphorin
binding molecules
neurodegenerative disorders
treating neurodegenerative
treating
Prior art date
Application number
PT148550742T
Other languages
English (en)
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of PT3060252T publication Critical patent/PT3060252T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT148550742T 2013-10-21 2014-10-21 Utilização de moléculas de ligação de semaforina-4d para tratar distúrbios neurodegenerativos PT3060252T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361893814P 2013-10-21 2013-10-21
US201461979384P 2014-04-14 2014-04-14
US201462012805P 2014-06-16 2014-06-16

Publications (1)

Publication Number Publication Date
PT3060252T true PT3060252T (pt) 2020-03-04

Family

ID=52826380

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148550742T PT3060252T (pt) 2013-10-21 2014-10-21 Utilização de moléculas de ligação de semaforina-4d para tratar distúrbios neurodegenerativos

Country Status (19)

Country Link
US (4) US9598495B2 (pt)
EP (2) EP3639853A1 (pt)
JP (2) JP6461944B2 (pt)
KR (4) KR102602502B1 (pt)
CN (2) CN106029093B (pt)
AU (3) AU2014340210B2 (pt)
BR (1) BR112016009047B1 (pt)
CA (2) CA2927841C (pt)
DK (1) DK3060252T3 (pt)
EA (1) EA033072B1 (pt)
ES (1) ES2773961T3 (pt)
IL (3) IL295045B2 (pt)
MX (2) MX2016005050A (pt)
NZ (1) NZ630892A (pt)
PL (1) PL3060252T3 (pt)
PT (1) PT3060252T (pt)
SG (2) SG10201707786QA (pt)
WO (1) WO2015061330A1 (pt)
ZA (1) ZA201602686B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010245668B2 (en) 2009-05-08 2016-07-14 Vaccinex, Inc. Anti-CD100 antibodies and methods for using the same
AU2012322721B2 (en) 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
US10626163B2 (en) * 2013-01-25 2020-04-21 Brandeis University Methods of modulating GABAergic inhibitory synapse formation and function
DK3013350T3 (da) 2013-06-25 2020-04-14 Vaccinex Inc Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
KR102558637B1 (ko) 2016-04-22 2023-07-24 백시넥스 인코포레이티드 폭스바이러스 세포외 피막형 비리온 상에서의 내재막 단백질 디스플레이
IL264343B2 (en) 2016-08-02 2024-05-01 Vaccinex Inc Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells
JP7084689B2 (ja) * 2016-12-08 2022-06-15 公益財団法人東京都医学総合研究所 脳組織の異常を伴う非ヒト動物の作製方法およびその利用
JP2020510845A (ja) * 2017-02-22 2020-04-09 バクシネックス インコーポレーティッド 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法
DK3600419T5 (en) 2017-03-20 2024-05-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
US11427634B2 (en) * 2017-05-05 2022-08-30 Vaccinex, Inc. Human anti-semaphorin 4D antibody
CN109410218B (zh) * 2018-10-08 2020-08-11 百度在线网络技术（北京）有限公司 用于生成车辆损伤信息的方法和装置
EP3693380A1 (en) * 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
WO2021262564A1 (en) * 2020-06-25 2021-12-30 Vaccinex, Inc. Use of semaphorin-4d binding molecules for the treatment of rett syndrome
WO2022137964A1 (ja) * 2020-12-23 2022-06-30 国立大学法人大阪大学 軟骨・骨・関節疾患の予防または治療用医薬組成物および軟骨・骨・関節疾患の予防または治療用薬剤のスクリーニング方法
MX2024003883A (es) * 2021-09-27 2024-08-28 Vaccinex Inc Perfil predictivo de resultados para el uso de una molecula de union de antisemaforina-4d para el tratamiento de trastornos neurodegenerativos.
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998046769A1 (en) 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
EP1137769B1 (en) 1998-11-10 2008-09-03 University Of Rochester Methods for the generation of dna libraries
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
WO2001046384A2 (en) 1999-12-23 2001-06-28 Cornell Research Foundation, Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
WO2002102972A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
BR0311471A (pt) 2002-05-30 2007-04-27 Macrogenics Inc anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
KR20120104408A (ko) 2003-05-30 2012-09-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
AU2004298483A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
RS51326B (sr) 2004-08-05 2010-12-31 Genentech Inc. Humanizovani anti-cmet antagonisti
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
JP2008535856A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌の診断、検出および治療におけるｓｅｍａ４ｄ
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
US20090181035A1 (en) 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
AU2010245668B2 (en) 2009-05-08 2016-07-14 Vaccinex, Inc. Anti-CD100 antibodies and methods for using the same
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
NZ605260A (en) 2010-06-14 2013-12-20 Joseph King Allan Anti-vegf antibodies and uses thereof
WO2012157237A1 (ja) 2011-05-13 2012-11-22 国立大学法人東京医科歯科大学 骨形成促進剤
AU2012322721B2 (en) * 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
DK3013350T3 (da) 2013-06-25 2020-04-14 Vaccinex Inc Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
KR102558637B1 (ko) 2016-04-22 2023-07-24 백시넥스 인코포레이티드 폭스바이러스 세포외 피막형 비리온 상에서의 내재막 단백질 디스플레이
IL264343B2 (en) 2016-08-02 2024-05-01 Vaccinex Inc Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells
JP2020510845A (ja) 2017-02-22 2020-04-09 バクシネックス インコーポレーティッド 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法

Also Published As

Publication number Publication date
MX2016005050A (es) 2016-08-17
AU2014340210B2 (en) 2019-08-08
KR20160065981A (ko) 2016-06-09
AU2021202095B9 (en) 2023-11-09
SG11201603167YA (en) 2016-05-30
AU2021202095B2 (en) 2023-11-02
US20150353641A1 (en) 2015-12-10
EA201690813A1 (ru) 2016-08-31
KR102602502B1 (ko) 2023-11-14
JP2019059786A (ja) 2019-04-18
AU2014340210A1 (en) 2016-05-05
IL245089A0 (en) 2016-06-30
US9598495B2 (en) 2017-03-21
CA2927841A1 (en) 2015-04-30
AU2021202095A1 (en) 2021-05-06
US10800853B2 (en) 2020-10-13
NZ630892A (en) 2016-03-31
KR102308493B1 (ko) 2021-10-07
IL295045B2 (en) 2024-04-01
IL245089B (en) 2020-10-29
US9249227B2 (en) 2016-02-02
CA2927841C (en) 2023-05-23
IL275720B (en) 2022-09-01
PL3060252T3 (pl) 2020-05-18
ZA201602686B (en) 2020-11-25
US10385136B2 (en) 2019-08-20
BR112016009047B1 (pt) 2024-02-06
BR112016009047A2 (pt) 2017-09-19
EA033072B1 (ru) 2019-08-30
US20170198053A1 (en) 2017-07-13
IL295045A (en) 2022-09-01
KR20220110853A (ko) 2022-08-09
JP6875363B2 (ja) 2021-05-26
JP2017502920A (ja) 2017-01-26
ES2773961T3 (es) 2020-07-15
US20150110800A1 (en) 2015-04-23
SG10201707786QA (en) 2017-10-30
WO2015061330A1 (en) 2015-04-30
JP6461944B2 (ja) 2019-01-30
EP3060252B1 (en) 2019-12-11
CN106029093A (zh) 2016-10-12
AU2019257379A1 (en) 2019-11-14
IL295045B1 (en) 2023-12-01
EP3060252A4 (en) 2017-06-07
KR20210118246A (ko) 2021-09-29
CN106029093B (zh) 2023-03-28
AU2019257379B2 (en) 2021-04-01
CN116966293A (zh) 2023-10-31
DK3060252T3 (da) 2020-03-16
IL275720A (en) 2020-08-31
US20190322757A1 (en) 2019-10-24
MX2020009260A (es) 2020-10-01
EP3060252A1 (en) 2016-08-31
CA3193983A1 (en) 2015-04-30
KR20230159633A (ko) 2023-11-21
EP3639853A1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
IL275720A (en) Use of molecules that bind semphorin-D4 for the treatment of neurodegenerative disorders
ZA201602577B (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis
EP2852388A4 (en) COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
IL243419A0 (en) Biomarkers for the treatment of neoplastic disorders using androgen-targeted therapies
HK1224182A1 (zh) 用於治療神經疾病的包含托拉塞米和巴氯芬的組合物
HK1214553A1 (zh) 用於治療神經退行性疾病的拉喹莫德和普利多匹定
EP2970317A4 (en) PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
HK1210593A1 (en) Tetracycline compounds for treating neurodegenerative disorders
EP2953950A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
HK1253717A1 (zh) 用於治療成骨不全的方法
GB201312279D0 (en) Neurodegenerative disorders
IL245541A0 (en) New methods for the treatment of neurodegenerative diseases
EP2976094A4 (en) METHOD FOR THE TREATMENT OF METABOLISM TROUBLES
IL276431A (en) Treatment of the brain disorders and related symptoms
HK1220453A1 (zh) 治療運動障礙和相關病症的方法
SG11201605292UA (en) Solubilisation of uv filters
HK1224220A1 (zh) 治療神經退化性失調的方法
EP2968550A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS
AU2013903509A0 (en) Device for treating respiratory disorders